BACKGROUND: Acid cysteine protease inhibitor (ACPI) is an intracellular protein, often linked to neoplastic changes in epithelium and thought to have an inhibitory role in malignant transformation. AIM: To analyse the expression and prognostic role of ACPI in non-small-cell lung cancer (NSCLC). METHOD: Histological samples from 199 patients with resected NSCLC were stained immunohistochemically for the expression of ACPI in normal and preneoplastic bronchial epithelium, and in various types of lung carcinomas. RESULTS: A normal bronchial epithelium showed positive staining for ACPI in the basal cells, whereas the upper two-thirds of the dysplastic epithelium was ACPI positive. High staining for ACPI was found in 74% (91/123) of squamous-cell carcinomas, whereas 16% (8/49) of adenocarcinomas and 30% of (8/27) large-cell carcinomas showed the high expression of ACPI (p<0.001). Among squamous-cell carcinomas, low expression of ACPI was correlated with poor tumour differentiation (p=0.032). In the whole tissue, reduced expression of ACPI was associated with tumour recurrence (p=0.024). In overall survival (OS) and disease-free survival (DFS) analyses, the histological type of the tumour (both p<0.001) and stage of the tumour (p=0.001, p=0.013, respectively) were related to patient outcome. Low expression of ACPI in tumour cells was associated with poor OS and DFS (p<0.041, p=0.004, respectively). In multivariate analysis, ACPI did not retain its prognostic value, whereas the traditional factors were the most important prognostic factors. CONCLUSIONS: ACPI expression is linked with the malignant transformation of the bronchial epithelium and predicts a risk of tumour recurrence as well as poor rate of survival for the patients. However, ACPI does not have any independent prognostic value in NSCLC.
BACKGROUND: Acid cysteine protease inhibitor (ACPI) is an intracellular protein, often linked to neoplastic changes in epithelium and thought to have an inhibitory role in malignant transformation. AIM: To analyse the expression and prognostic role of ACPI in non-small-cell lung cancer (NSCLC). METHOD: Histological samples from 199 patients with resected NSCLC were stained immunohistochemically for the expression of ACPI in normal and preneoplastic bronchial epithelium, and in various types of lung carcinomas. RESULTS: A normal bronchial epithelium showed positive staining for ACPI in the basal cells, whereas the upper two-thirds of the dysplastic epithelium was ACPI positive. High staining for ACPI was found in 74% (91/123) of squamous-cell carcinomas, whereas 16% (8/49) of adenocarcinomas and 30% of (8/27) large-cell carcinomas showed the high expression of ACPI (p<0.001). Among squamous-cell carcinomas, low expression of ACPI was correlated with poor tumour differentiation (p=0.032). In the whole tissue, reduced expression of ACPI was associated with tumour recurrence (p=0.024). In overall survival (OS) and disease-free survival (DFS) analyses, the histological type of the tumour (both p<0.001) and stage of the tumour (p=0.001, p=0.013, respectively) were related to patient outcome. Low expression of ACPI in tumour cells was associated with poor OS and DFS (p<0.041, p=0.004, respectively). In multivariate analysis, ACPI did not retain its prognostic value, whereas the traditional factors were the most important prognostic factors. CONCLUSIONS: ACPI expression is linked with the malignant transformation of the bronchial epithelium and predicts a risk of tumour recurrence as well as poor rate of survival for the patients. However, ACPI does not have any independent prognostic value in NSCLC.
Authors: A A Sinha; B J Quast; M J Wilson; E T Fernandes; P K Reddy; S L Ewing; B F Sloane; D F Gleason Journal: Prostate Date: 2001-09-15 Impact factor: 4.104
Authors: Akhouri A Sinha; Barry J Quast; Michael J Wilson; Eduardo T Fernandes; Pratap K Reddy; Stephen L Ewing; Donald F Gleason Journal: Cancer Date: 2002-06-15 Impact factor: 6.860
Authors: S M Jamshedur Rahman; Adriana L Gonzalez; Ming Li; Erin H Seeley; Lisa J Zimmerman; Xueqiong J Zhang; M Lisa Manier; Sandra J Olson; Ronak N Shah; Alison N Miller; Joe B Putnam; York E Miller; Wilbur A Franklin; William J Blot; David P Carbone; Yu Shyr; Richard M Caprioli; Pierre P Massion Journal: Cancer Res Date: 2011-04-12 Impact factor: 12.701
Authors: Marcus W Butler; Tomoya Fukui; Jacqueline Salit; Renat Shaykhiev; Jason G Mezey; Neil R Hackett; Ronald G Crystal Journal: Cancer Res Date: 2011-02-16 Impact factor: 12.701
Authors: Julia Beretov; Valerie C Wasinger; Ewan K A Millar; Peter Schwartz; Peter H Graham; Yong Li Journal: PLoS One Date: 2015-11-06 Impact factor: 3.240